RRS® HA Long Lasting Wins Best Injectable at AMWC 2026

The award recognizes the product as a leader in the emerging Skin Builder category, a hybrid classification that bridges the gap between traditional dermal fillers and skin boosters. By combining cross-linked hyaluronic acid with a protective buffer of 15 amino acids, the treatment aims to improve skin texture, hydration, and firmness while providing a subtle lifting effect. Unlike standard procedures, this dual-action approach targets both immediate aesthetic improvement and long-term dermal health.

Márcio Rodrigues, CEO of Skin Tech Pharma Group, described the accolade as a validation of the company's focus on scientific rigor and evidence-based innovation. Clinical observations support this, with Dr. Javed Hussain noting that the product delivers reproducible results and durability that frequently exceed expectations for conventional boosters. As the company celebrates its 30th anniversary, this recognition underscores its strategy of integrating pharmaceutical standards into the competitive landscape of aesthetic medicine.